Press coverage about Chiasma (NASDAQ:CHMA) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chiasma earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.5327861599109 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Separately, ValuEngine upgraded shares of Chiasma from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

Chiasma (NASDAQ:CHMA) traded up 5.45% during midday trading on Friday, hitting $2.90. 65,612 shares of the stock traded hands. The company’s market capitalization is $70.64 million. Chiasma has a 52 week low of $1.55 and a 52 week high of $3.19. The stock’s 50-day moving average price is $2.48 and its 200 day moving average price is $2.48.

In other news, Director Scott Minick bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 21st. The shares were bought at an average cost of $2.37 per share, with a total value of $59,250.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.80% of the stock is owned by insiders.

WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at

About Chiasma

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Insider Buying and Selling by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.